Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plasma Biomarker in Predicting Response and Toxicity in Hepatocellular Carcinoma Patients Treated With Checkpoint Inhibitors With or Without Sterotatic Body Radiotherapy

NCT06408753 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06408753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06408753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plasma Biomarker in Predicting Response and Toxicity in Hepatocellular Carcinoma Patients Treated With Checkpoint Inhibitors With or Without Sterotatic Body Radiotherapy
Lead sponsor
The University of Hong Kong
Phase
Observational
Overall status
Completed
Start date
November 1, 2019
Completion date
March 27, 2024
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable, stereotactic body radiotherapy